







“We report a consistent increase in the risk of persistent symptoms after reinfection compared to first infection. All post-acute symptoms mentioned in the WHO clinical case definition appeared more common after reinfection than after a 1st infection”‘RoBuSt HyBriD iMmuNiTy’ 🤪 pic.twitter.com/eIe3IBYyrk— Dr. Lisa Iannattone (@lisa_iannattone) November 17, 2023
Long-COVID recovery varies sharply by symptoms, study finds
Fewer than one in five people with multiple body systems impacted experience sustained improvement within three years of infection, a study found.

Vaccination Dramatically Lowers Long COVID Risk
Several new studies reveal that getting multiple COVID vaccine doses provides strong protection against lingering symptoms

Long COVID: How COVID-19 may lead to vicious viral cycle
COVID-19 was linked to the reactivation of several dormant viruses in unvaccinated people, a new study has found. One of the reactivated viruses was also linked to long COVID.

Timing of Long COVID Improvement in Prospectively Followed RECOVER-Adult Participants
Background: Long COVID (LC) is widespread; however, limited information has been reported on the likelihood that symptoms remit over time. Objective: To evaluate the likelihood of improvement among persons with likely LC. Design: Prospective, multisite cohort study (RECOVER-Adult [Researching COVID to Enhance Recovery]). Setting: 83 U.S.-based sites across 33 states; Washington, DC; and Puerto Rico. Participants: 1019 persons in RECOVER-Adult with likely LC (LC Research Index [LCRI] ≥11) 12 months after first SARS-CoV-2 infection. Measurements: The primary outcome was time until 2 consecutive study visits with LCRI less than 11. Secondary outcomes were time until LCRI measure reduced 50% or more and quality of life was good or better, and LCRI decreased to 0. Unadjusted estimates of cumulative incidence and adjusted marginal cumulative incidence by age, sex, SARS-CoV-2 wave, and LC subtype were reported across all follow-up time points. Results: An estimated 36.2% (95% CI, 33.0% to 39.5%) met the primary outcome by 24 months after infection, and 50.1% (CI, 46.1% to 54.0%) met the primary outcome by 36 months. An estimated 56.4% (CI, 52.2% to 60.4%) and 26.9% (CI, 23.3% to 30.5%), respectively, met the 2 secondary outcomes by 36 months. Among persons who still reported likely LC at 18 months and 24 months after first infection, relative timing of subsequent symptom improvement was similar. Limitation: Findings in this observational cohort are interpretable in a population with prevalent likely LC and do not address causal relationships between individual characteristics and symptom improvement. Conclusion: Among persons with likely LC 12 months after initial SARS-CoV-2 infection, one half experience meaningful reductions in symptoms by 36 months, whereas a quarter experience complete remission of symptoms. These findings underscore both the potential for natural recovery and the urgent need for placebo-controlled therapeutic intervention trials. Primary Funding Source: National Institutes of Health.

Timing of Long COVID Improvement in Prospectively Followed RECOVER-Adult Participants
Background: Long COVID (LC) is widespread; however, limited information has been reported on the likelihood that symptoms remit over time. Objective: To evaluate the likelihood of improvement among persons with likely LC. Design: Prospective, multisite cohort study (RECOVER-Adult [Researching COVID to Enhance Recovery]). Setting: 83 U.S.-based sites across 33 states; Washington, DC; and Puerto Rico. Participants: 1019 persons in RECOVER-Adult with likely LC (LC Research Index [LCRI] ≥11) 12 months after first SARS-CoV-2 infection. Measurements: The primary outcome was time until 2 consecutive study visits with LCRI less than 11. Secondary outcomes were time until LCRI measure reduced 50% or more and quality of life was good or better, and LCRI decreased to 0. Unadjusted estimates of cumulative incidence and adjusted marginal cumulative incidence by age, sex, SARS-CoV-2 wave, and LC subtype were reported across all follow-up time points. Results: An estimated 36.2% (95% CI, 33.0% to 39.5%) met the primary outcome by 24 months after infection, and 50.1% (CI, 46.1% to 54.0%) met the primary outcome by 36 months. An estimated 56.4% (CI, 52.2% to 60.4%) and 26.9% (CI, 23.3% to 30.5%), respectively, met the 2 secondary outcomes by 36 months. Among persons who still reported likely LC at 18 months and 24 months after first infection, relative timing of subsequent symptom improvement was similar. Limitation: Findings in this observational cohort are interpretable in a population with prevalent likely LC and do not address causal relationships between individual characteristics and symptom improvement. Conclusion: Among persons with likely LC 12 months after initial SARS-CoV-2 infection, one half experience meaningful reductions in symptoms by 36 months, whereas a quarter experience complete remission of symptoms. These findings underscore both the potential for natural recovery and the urgent need for placebo-controlled therapeutic intervention trials. Primary Funding Source: National Institutes of Health.

COVID survivors at increased risk of long-term gastrointestinal conditions
Although people with severe COVID had highest risk, mild cases also upped risks.

The CDC whispered this a year ago. “SARS-CoV-2 can have lasting effects on nearly every organ & organ system of the body weeks, months, & potentially years after infection. Documented serious post-Covid conditions include cardiovascular, pulmonary, neurological, renal, endocrin
The CDC whispered this a year ago. “SARS-CoV-2 can have lasting effects on nearly every organ & organ system of the body weeks, months, & potentially years after infection. Documented serious post-Covid conditions include cardiovascular, pulmonary, neurological, renal,… pic.twitter.com/xkSStj51y2— Laura Miers (@LauraMiers) March 9, 2024
Almost a third of recovered Covid patients return to hospital in five months and one in eight die
Almost a third of recovered Covid patients will end up back in hospital within five months and one in eight will die, alarming new figures have shown. Research by Leicester University and the Office f...
COVID's aftermath: Persistent organ damage at 1 year, lung abnormalities at 2
CIDRAP - Center for Infectious Disease Research & PolicyResearch and Innovation Office, University of Minnesota, Minneapolis, MN

GUESS WHAT?! A new study has shown SARS-CoV-2 infection is DISTINCT from common respiratory viruses! Unequivocally, COVID is NOT "just a cold." These findings are HUGELY significant, for multiple reasons! Here's a breakdown of the study (writt
GUESS WHAT?! A new study has shown SARS-CoV-2 infection is DISTINCT from common respiratory viruses!Unequivocally, COVID is NOT "just a cold."These findings are HUGELY significant, for multiple reasons! Here's a breakdown of the study (written for a general audience)...1/16 pic.twitter.com/P7NJL2STJQ— Nick #RespiratorsFilterAllPathogens😷 Anderegg (@NickAnderegg) July 7, 2024
Mixing Covid jabs has good immune response, study finds
Any combination of Pfizer or AstraZeneca for first and second doses works, a study suggests.

The 300-year journey to the covid vaccine: From inoculation to RNA
The history of immunization technology is a quest to achieve immunity with ever-more safety and ever-fewer side effects
People With Multisystem Long Covid See Lower Recovery, Research Finds
People whose long Covid affects multiple body systems are far less likely to improve than overall recovery estimates suggest, with fewer than one in five experiencing sustained improvement within three years of infection, according to a US study.

Why Is Everyone Getting Sick? Behind the Global Rise in RSV, Flu, Measles
It's not your imagination: At least 13 communicable diseases are surging past pre-pandemic levels

Long emergencies: Covid, climate, homelessness
At first, U.S. society treated the Covid-19 pandemic as an emergency requiring collective solutions. Now we pretend it’s over and treat staying healthy as an individual matter. I live in San Francisco and hang out in progressive spaces that were some of the last holdouts in urging and giving out masks. Now, even though the new Covid surge is making more of my friends sick than ever, masks are a rare sight. Anywhere outside SF, they’re unheard of. Collective health is out; rugged individualism is in. If you’re immunocompromised: sorry, but everyone’s tired of being inconvenienced just for the small matter of your survival. We’re living in the “You do you” era.
Japan: A study covering 2020–2023 estimated COVID-19 infections were 4.7x higher than officially reported. During Omicron BA.4/5: • Reinfection rate rose from 0.4% (2021) to 28.1% (2023) • Reinfections made up 81.5% of new infections • Findings highlight widespread underreporting and reinfections